These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32841278)

  • 1. Restricting extracellular Ca2+ on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca2+ response, which consequently enhances gefitinib sensitivity.
    Kim MS; Kim SH; Yang SH; Kim MS
    PLoS One; 2020; 15(8):e0238155. PubMed ID: 32841278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non-small-cell lung cancer.
    Shuai S; Liao X; Wang H; Liu L; Mei S; Cao J; Wang S
    Cancer Sci; 2021 Oct; 112(10):4139-4150. PubMed ID: 34058054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
    Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
    Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Anti-EGFR/anti- HER2 Bispecific Antibody with Enhanced Antitumor Activity Against Acquired Gefitinib-Resistant NSCLC Cells.
    Si Y; Pei X; Wang X; Han Q; Xu C; Zhang B
    Protein Pept Lett; 2021; 28(11):1290-1297. PubMed ID: 34602035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
    Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
    Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
    Sun C; Gao W; Liu J; Cheng H; Hao J
    Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPARα agonist fenofibrate relieves acquired resistance to gefitinib in non-small cell lung cancer by promoting apoptosis via PPARα/AMPK/AKT/FoxO1 pathway.
    Wang MS; Han QS; Jia ZR; Chen CS; Qiao C; Liu QQ; Zhang YM; Wang KW; Wang J; Xiao K; Ding XS
    Acta Pharmacol Sin; 2022 Jan; 43(1):167-176. PubMed ID: 33772142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced expression of CYLD promotes cell survival and inflammation in gefitinib-treated NSCLC PC-9 cells: Targeting CYLD may be beneficial for acquired resistance to gefitinib therapy.
    Yuan Y; Liu L; Wang Y; Liu S
    Cell Biol Int; 2020 Sep; 44(9):1911-1918. PubMed ID: 32441799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib.
    Cheng H; An SJ; Dong S; Zhang YF; Zhang XC; Chen ZH; Jian-Su ; Wu YL
    J Hematol Oncol; 2011 Jan; 4():5. PubMed ID: 21255411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells.
    Jia Z; Zhang Y; Yan A; Wang M; Han Q; Wang K; Wang J; Qiao C; Pan Z; Chen C; Hu D; Ding X
    Cell Death Dis; 2020 Aug; 11(8):670. PubMed ID: 32820157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer.
    Hidayat M; Mitsuishi Y; Takahashi F; Tajima K; Yae T; Miyahara K; Hayakawa D; Winardi W; Ihara H; Koinuma Y; Wirawan A; Nurwidya F; Kato M; Kobayashi I; Sasaki S; Takamochi K; Hayashi T; Suehara Y; Moriyama M; Moriyama H; Habu S; Takahashi K
    Bosn J Basic Med Sci; 2019 Nov; 19(4):355-367. PubMed ID: 31202256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omega-3 Fatty Acid-Enriched Fish Oil and Selenium Combination Modulates Endoplasmic Reticulum Stress Response Elements and Reverses Acquired Gefitinib Resistance in HCC827 Lung Adenocarcinoma Cells.
    Liao CH; Tzeng YT; Lai GM; Chang CL; Hu MH; Tsai WL; Liu YR; Hsia S; Chuang SE; Chiou TJ; Wang LM; Whang-Peng J; Yao CJ
    Mar Drugs; 2020 Jul; 18(8):. PubMed ID: 32751169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAGE potentiates EGFR signaling and interferes with the anticancer effect of gefitinib on NSCLC cells.
    Liao WL; Lin H; Li YH; Yang TY; Chen MC
    Am J Physiol Cell Physiol; 2023 Nov; 325(5):C1313-C1325. PubMed ID: 37746694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib.
    Ando K; Ohmori T; Inoue F; Kadofuku T; Hosaka T; Ishida H; Shirai T; Okuda K; Hirose T; Horichi N; Nishio K; Saijo N; Adachi M; Kuroki T
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8872-9. PubMed ID: 16361577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
    Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M
    Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PLCγ1‑dependent invasion and migration of cells expressing NSCLC‑associated EGFR mutants.
    Mittal S; Kamath A; Joseph AM; Rajala MS
    Int J Oncol; 2020 Oct; 57(4):989-1000. PubMed ID: 32945365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance.
    Zhang SR; Xu YS; Jin E; Zhu LC; Xia B; Chen XF; Li FZ; Ma SL
    Acta Pharmacol Sin; 2017 Jan; 38(1):100-109. PubMed ID: 27840409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers.
    Busser B; Sancey L; Josserand V; Niang C; Favrot MC; Coll JL; Hurbin A
    Mol Ther; 2010 Mar; 18(3):528-35. PubMed ID: 19826406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-145 changes sensitivity of non-small cell lung cancer to gefitinib through targeting ADAM19.
    Wang Y; Lian YM; Ge CY
    Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5831-5839. PubMed ID: 31298334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.